Brief: Evotec Receives $25 Mln Payment From Bristol Myers Squibb To Support Joint Programs
Oct 27 (Reuters) - EVOTEC SE EVTG.DE: EVOTEC ANNOUNCES PROGRESS IN PRECLINICAL NEUROSCIENCE PARTNERSHIP WITH BRISTOL MYERS SQUIBB EVOTEC RECEIVES US$ 25 M PAYMENT TO SUPPORT CONTINUED PROGRESSION OF JOINT PROGRAMS PAYMENT FROM BRISTOL MYERS SQUIBB WILL ADVANCE FURTHER RESEARCH AND PARTNERS' JOINT PIPELINE OF PROGRAMS AIMED AT TACKLING NEUROGENERATIVE DISEASE Source text: ID:nEQbr5NG8a Further company coverage: EVTG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases